This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (35)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Topic Collections  • Randomized Controlled Trial  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

Results From the INSIGHT Trial

Peter W. de Leeuw, MD, PhD; Luis M. Ruilope, MD, PhD; Christopher R. Palmer, PhD; Morris J. Brown, MD, PhD; Alain Castaigne, MD, PhD; Giuseppe Mancia, MD, PhD; Talma Rosenthal, MD, PhD; Gilbert Wagener, MD

Arch Intern Med. 2004;164:2459-2464.

Background  Increasing evidence suggests renal involvement in hypertension-related cardiovascular and cerebrovascular complications. To assess this role of renal function in more detail, we studied the evolution of renal function and the relationship of renal function with mortality and morbidity in the Intervention as a Goal in Hypertension Treatment (INSIGHT) study.

Methods  The INSIGHT study was a double-blind, randomized, multicenter trial in patients with hypertension and at least 1 additional cardiovascular risk factor. Treatment consisted of nifedipine gastrointestinal therapeutic system, 30 mg/d, or hydrochlorothiazide-amiloride (25 mg/d of hydrochlorothiazide and 2.5 mg/d of amiloride hydrochloride). Primary outcome was a composite of cardiovascular death, myocardial infarction, heart failure, and stroke. Renal function was assessed by measuring creatinine clearance, serum creatinine level, and serum uric acid level and by the presence of proteinuria.

Results  Creatinine clearance fell more in nifedipine recipients than in hydrochlorothiazide-amiloride recipients. Renal insufficiency developed in 2% of nifedipine recipients and 5% of hydrochlorothiazide-amiloride recipients. Primary outcomes occurred in 15% of patients with increased serum creatinine levels and 6% of patients with normal levels (odds ratio [OR] 2.89; 95% confidence interval [CI], 1.92-4.36; P<.001). Primary outcomes were more likely in patients with low creatinine clearance (<60 mL/min) than in those with higher clearances (9% vs 5%, respectively [OR, 1.51, 95%CI, 1.22-1.88; P<.001]).

Conclusions  Renal function is an important predictor of risk in hypertensive patients at high risk. Antihypertensive treatment with a long-acting dihydropyridine calcium channel blocker may better preserve renal function than would treatment with diuretics.

Author Affiliations: Department of Medicine, University Hospital Maastricht, Maastricht, the Netherlands (Dr de Leeuw); Unidad de Hipertension, Hospital 12 de Octobre, University of Madrid, Madrid, Spain (Dr Ruilope); Centre for Applied Medical Statistics (Dr Palmer) and Clinical Pharmacology Unit (Dr Brown), University of Cambridge, Cambridge, England; Hopital Henri-Mondor, Creteil, Paris, France (Dr Castaigne); Cattedra di Medicina Interna, University of Milano-Bicocca, St Gerardo Hospital, Monza, Italy (Dr Mancia); Hypertension Unit, the Chaim Sheba Medical Centre, University of Tel Aviv, Tel Aviv, Israel (Dr Rosenthal); and Bayer AG, Pharma Research Center, Wuppertal, Germany (Dr Wagener).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Can Calcium Channel Blockers Preserve Renal Function Better Than Diuretics During Antihypertensive Treatment?
Michio Fukuda and Genjiro Kimura
Arch Intern Med. 2005;165(11):1312.
EXTRACT | FULL TEXT  

Can Calcium Channel Blockers Preserve Renal Function Better Than Diuretics During Antihypertensive Treatment?—Reply
Peter W. de Leeuw, Luis M. Ruilope, and for the INSIGHT Investigators
Arch Intern Med. 2005;165(11):1312-1313.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Blood Pressure-Independent Reduction in Proteinuria and Arterial Stiffness After Acute Endothelin-A Receptor Antagonism in Chronic Kidney Disease
Dhaun et al.
Hypertension 2009;54:113-119.
ABSTRACT | FULL TEXT  

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Authors/Task Force Members: et al.
Eur Heart J 2007;0:ehm236v1-75.
FULL TEXT  

Effect of Barnidipine on Blood Pressure and Serum Metabolic Parameters in Patients With Essential Hypertension: A Pilot Study
Spirou et al.
J CARDIOVASC PHARMACOL THER 2006;11:256-261.
ABSTRACT  

Chronic Kidney Disease and Mortality Risk: A Systematic Review
Tonelli et al.
J. Am. Soc. Nephrol. 2006;17:2034-2047.
ABSTRACT | FULL TEXT  

Essential Hypertension, Progressive Renal Disease, and Uric Acid: A Pathogenetic Link?
Johnson et al.
J. Am. Soc. Nephrol. 2005;16:1909-1919.
ABSTRACT | FULL TEXT  

Can Calcium Channel Blockers Preserve Renal Function Better Than Diuretics During Antihypertensive Treatment?
Fukuda and Kimura
Arch Intern Med 2005;165:1312-1312.
FULL TEXT  

Can Calcium Channel Blockers Preserve Renal Function Better Than Diuretics During Antihypertensive Treatment?--Reply
de Leeuw et al.
Arch Intern Med 2005;165:1312-1313.
FULL TEXT